Elon Musk’s Neuralink has implanted its “Telepathy” brain-computer interface in seven people with severe paralysis, more than doubling the patient count since February, the company disclosed in a Summer 2025 update. The N1 implant lets users move a computer cursor and perform routine tasks by thought alone; the first Miami recipient has already used it to operate a television and navigate the internet, local clinicians said. Neuralink also said it has obtained regulatory clearance to begin human trials in Canada and the United Arab Emirates, its first approvals outside the United States and a step toward a broader, multicountry study. Six of the current patients are enrolled in the PRIME trial run by the Barrow Neurological Institute, while the seventh was treated at the University of Miami Health System. Looking ahead, the company plans to place electrodes directly in the speech cortex as early as the third quarter of 2025 to translate intended words into synthesized speech. Its published roadmap calls for tripling electrode counts, enabling navigation for blind users and supporting multiple implants between 2026 and 2027, and scaling to a 25,000-channel system that can reach any brain region by 2028. The fast-growing trial program positions Neuralink at the forefront of an increasingly crowded brain-computer interface field, even as the company faces ongoing scrutiny over animal testing practices and data-privacy concerns raised by ethicists.